Skip to main navigation Skip to search Skip to main content

Identification of Epithelial Cell Adhesion Molecule Autoantibody in Patients with Ovarian Cancer

  • Jae Hoon Kim
  • , Dorothee Herlyn
  • , Kwong Kwok Wong
  • , Dong Choon Park
  • , John O. Schorge
  • , Karen H. Lu
  • , Steven J. Skates
  • , Daniel W. Cramer
  • , Ross S. Berkowitz
  • , Samuel C. Mok
  • Brigham and Women’s Hospital
  • The Catholic University of Korea, St. Vincent's Hospital
  • Wistar Institute
  • Baylor College of Medicine
  • University of Texas Southwestern Medical Center
  • University of Texas MD Anderson Cancer Center
  • Dana-Farber Harvard Cancer Center

Research output: Contribution to journal › Article › peer-review

78 Scopus citations

Abstract

The epithelial cell adhesion molecule (Ep-CAM) exhibited an ovarian cancer: normal human ovarian surface epithelium ratio of 444. For validation studies, real-time quantitative PCR analysis and immunohistochemistry were performed in normal and malignant ovarian epithelial cell lines and tissues. To evaluate the potential of the Ep-CAM autoantibody as a tumor marker, we examined the amount of Ep-CAM autoantibody in serum samples obtained from ovarian cancer patients and normal controls by an ELISA. Real-time quantitative PCR analysis revealed significant overexpression of Ep-CAM mRNA in cancer cell lines (P < 0.001) and microdissected cancer tissues (P < 0.05), compared with that in cultured normal human ovarian surface epithelium and microdissected germinal epithelium, respectively. Immunolocalization of the Ep-CAM autoantibody showed that the sera of ovarian cancer patients expressed higher levels of Ep-CAM autoantibody than benign tumor patients and normal controls (P < 0.05). The levels of Ep-CAM autoantibody found were as follows: 0.132 in 52 patients with ovarian cancer, 0.098 in 26 cases with benign gynecologic disease, and 0.090 in 26 normal women. This investigation has shown that the Ep-CAM autoantibody was found to be associated with ovarian cancer and suggested that future research assessing its clinical usefulness would be worthwhile.

Original languageEnglish
Pages (from-to)4782-4791
Number of pages10
JournalClinical Cancer Research
Volume9
Issue number13
StatePublished - 15 Oct 2003

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Identification of Epithelial Cell Adhesion Molecule Autoantibody in Patients with Ovarian Cancer'. Together they form a unique fingerprint.

Cite this